Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 791.91M P/E - EPS this Y 14.50% Ern Qtrly Grth -
Income -237.73M Forward P/E -3.75 EPS next Y -0.70% 50D Avg Chg -21.00%
Sales 314k PEG - EPS past 5Y - 200D Avg Chg -31.00%
Dividend N/A Price/Book 3.67 EPS next 5Y - 52W High Chg -53.00%
Recommedations 1.50 Quick Ratio 17.93 Shares Outstanding 62.77M 52W Low Chg 38.00%
Insider Own 1.02% ROA -34.37% Shares Float 47.94M Beta 1.10
Inst Own 100.97% ROE -56.80% Shares Shorted/Prior 9.73M/7.62M Price 18.36
Gross Margin - Profit Margin - Avg. Volume 796,129 Target Price 38.27
Oper. Margin -99,275.00% Earnings Date May 8 Volume 500,040 Change -1.55%
About Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Viridian Therapeutics, Inc. News
04/29/24 Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
04/04/24 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/05/24 Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
02/29/24 Viridian Therapeutics Full Year 2023 Earnings: Misses Expectations
02/27/24 Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
02/16/24 Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
01/17/24 Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
01/17/24 Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
01/08/24 Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
01/04/24 Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
12/18/23 Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease
11/21/23 Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
11/13/23 Viridian Therapeutics Inc (VRDN) Reports Q3 2023 Financial Results and Corporate Progress
11/13/23 Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/08/23 Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference
11/03/23 Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology
07:30 AM Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing
10/26/23 Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease
09/25/23 Insider Traders Lose US$114k As Viridian Therapeutics Drops
09/25/23 Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors
VRDN Chatroom

User Image Blink182rulez Posted - 8 hours ago

$VRDN pathetic

User Image Stock_Titan Posted - 20 hours ago

$VRDN Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024 https://www.stocktitan.net/news/VRDN/viridian-therapeutics-to-webcast-first-quarter-2024-financial-1mysepa9g4as.html

User Image MUNEMAKER Posted - 3 days ago

$VRDN Pathetic bounce

User Image aliliimr Posted - 4 days ago

$VRDN added at 12.4

User Image KWalzz Posted - 5 days ago

$VRDN mad move. is Scott Myers back?

User Image alejopa2001 Posted - 5 days ago

$VRDN WTF is this?

User Image MUNEMAKER Posted - 5 days ago

$VRDN Any apparent justification for this other than the dead time between catalysts and the typical sector pressure?

User Image frontiere Posted - 1 week ago

$SLRN Accelyrin ref=$4.96 long starter with partial stop-loss below 4.8 in case it’s not a bottom… +pending more due dil EOY cash 721 add in 30M refund from CRO =$751M ➔>$200m negative EV (though annual cash burn almost half of cash on hand). busted IPO, a long saga of weirdness, but IL-17a inhibitor and tons of cash. HS Phase 3 in 2H24 Comp $MLTX Moonlake positive EV=~$2.1B ⁉️ + comp $VRDN Viridian positive EV=~+300m after Jan financing — whose data they dunk on in their latest deck.

User Image NeverPop Posted - 1 week ago

$VRDN -38% YTD Not terrible

User Image Rodmon77 Posted - 1 week ago

$VRDN Manipulated badly to the downside for no apparent reason 🔥

User Image R_NW Posted - 2 weeks ago

$VRDN Added a position earlier in the week.

User Image G101SPM Posted - 2 weeks ago

#OPTIONACTION $CFG May 35 calls (volume: 3280, open int: 10, implied vol: ~38%, prev day implied vol: 35%). Co is confirmed to report earnings April 17 before the open. $GILD Weekly May03 69 calls (volume: 14.9K, open int: 0, implied vol: ~28%, prev day implied vol: 26%). 14.9K traded in a single transaction. Co is confirmed to report earnings April 25 after the close. $VRDN May 15 puts are seeing interest with the underlying stock down 6% (volume: 5000, open int: 0, implied vol: ~86%, prev day implied vol: 74%). Nearly all the volume occurred in a single transaction. Co is expected to report earnings early May.K $SLG Jun 55 puts are seeing interest with the underlying stock down 7% (volume: 2510, open int: 0, implied vol: ~56%, prev day implied vol: 52%). Co is confirmed to report earnings April 17 after the close.

User Image Stock_Titan Posted - 3 weeks ago

$VRDN Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/VRDN/viridian-therapeutics-announces-inducement-grants-under-nasdaq-7pergfgvh6zj.html

User Image danieltanner Posted - 3 weeks ago

$VRDN is a 3 month low bad?

User Image Blink182rulez Posted - 1 month ago

$VRDN

User Image Motohead125 Posted - 1 month ago

$VRDN who is adding here?

User Image FyCkD_FuNnY Posted - 1 month ago

$VRDN Down 7% $SLDB Up 73% $FUSN Up 90% 2/3 Not Bad for 51 Days... Perceptive👈👀🦏

User Image mv21970 Posted - 1 month ago

$TRML is down 38% because its drug is similar to Chugais but $VRDN which also has the same "problem" is only down 1% .. looks like bigtime overreaction to me

User Image Thestocktraderhubzee Posted - 1 month ago

WATCHLIST MAR 21 2024 $RGF The Real Good Food shares are trading lower after B. Riley Securities downgraded the stock from Buy to Neutral and lowered its price target from $6 to $0.50. $STNE Citigroup Maintains Buy on StoneCo, Raises Price Target to $20 $BAC Citigroup Maintains Neutral on Bank of America, Raises Price Target to $39 $SOUN Cantor Fitzgerald Downgrades SoundHound AI to Underweight, Lowers Price Target to $4.9 $VRDN Needham Maintains Buy on Viridian Therapeutics, Maintains $30 Price Target

User Image Blink182rulez Posted - 1 month ago

$VRDN this is a $40 stock easily right?

User Image FannyPackin Posted - 1 month ago

$VRDN low volume drop, probably a good buy point here under 18, grabbed some July 22.5c just a bit ago.. still holding shares for next trim ~26-27..

User Image MUNEMAKER Posted - 1 month ago

$VRDN The hell is going on here?

User Image Stock_Titan Posted - 1 month ago

$VRDN Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/VRDN/viridian-therapeutics-announces-inducement-grants-under-nasdaq-ye26zrab1p4d.html

User Image Stock_Titan Posted - 1 month ago

$VRDN Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference https://www.stocktitan.net/news/VRDN/viridian-therapeutics-to-participate-in-the-leerink-partners-global-s1do4yusbv87.html

User Image Rodmon77 Posted - 1 month ago

$VRDN Runner 🏃‍♂️ 🏃‍♀️ Potential 🤫👉

User Image Thestocktraderhubzee Posted - 1 month ago

WATCHLIST MAR 01 2024. $LYEL HC Wainwright & Co. Maintains Buy on Lyell Immunopharma, Lowers Price Target to $6 $VRDN HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $37 Price Target $OLPX Telsey Advisory Group Reiterates Market Perform on Olaplex Hldgs, Maintains $2 Price Target $MIRM HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $45 $STRA Barrington Research Maintains Outperform on Strategic Education, Raises Price Target to $125

User Image R_NW Posted - 2 months ago

@FannyPackin all 3 of the stocks ($nbix $vrdn $ewtx) mentioned by the analyst on cnbc are down today. Beware of pumpers and dumpers they are everywhere!

User Image FannyPackin Posted - 2 months ago

$VRDN first time I’ve ever seen it mentioned on CNBC(along with $NBIX).. been consolidating, think 35 in da summer..

User Image Ninja_Tradez Posted - 2 months ago

📢 $VRDN - Needham Reiterates Buy on Viridian Therapeutics, Maintains $30 Price Target https://newsfilter.io/a/e4d474b5f98f90293aadeb1fb98badcc

User Image epsguid Posted - 2 months ago

$VRDN reported a loss of $1.35, consensus was ($1.08) via @eWhispers #epsmiss http://eps.sh/d/vrdn

Analyst Ratings
B. Riley Securities Buy Mar 21, 24
Needham Buy Mar 20, 24
HC Wainwright & Co. Buy Feb 29, 24
Wedbush Outperform Feb 28, 24
Needham Buy Feb 28, 24
Oppenheimer Outperform Dec 19, 23
HC Wainwright & Co. Buy Dec 18, 23
RBC Capital Outperform Dec 14, 23
Wedbush Outperform Dec 4, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Fairmount Funds Management LLC Director Director Jan 22 Buy 21.00 476,190 9,999,990 1,839,954 01/24/24
Meisner Lara Chief Legal Officer Chief Legal Officer Jun 02 Sell 24.75 7,500 185,625 29,971 06/06/23
Meisner Lara Chief Legal Officer Chief Legal Officer Jun 02 Option 17.01 7,500 127,575 35,097 06/06/23
Myers Scott Dunseth Chief Executive Offi.. Chief Executive Officer Apr 12 Buy 25.3697 4,000 101,479 259,500 04/12/23
Meisner Lara General Counsel and.. General Counsel and Secretary Mar 09 Sell 29.07 29,971 871,257 03/10/23
Violin Jonathan Chief Executive Off.. Chief Executive Officer Feb 02 Sell 36.8 50,000 1,840,000 480,905 02/07/23
Violin Jonathan Chief Executive Off.. Chief Executive Officer Feb 02 Option 0.15 50,000 7,500 530,905 02/07/23
Meisner Lara General Counsel and.. General Counsel and Secretary Jan 23 Sell 35.66 6,843 244,021 01/25/23
Meisner Lara General Counsel and.. General Counsel and Secretary Jan 23 Option 18.52 6,843 126,732 6,843 01/25/23
Katz Barrett Chief Medical Office.. Chief Medical Officer Jan 13 Sell 37.11 29,000 1,076,190 01/18/23
Katz Barrett Chief Medical Office.. Chief Medical Officer Jan 13 Option 23.03 29,000 667,870 24,853 01/18/23
Katz Barrett Chief Medical Office.. Chief Medical Officer Jan 09 Sell 34.17 60,000 2,050,200 01/11/23
Katz Barrett Chief Medical Office.. Chief Medical Officer Jan 09 Option 23.03 60,000 1,381,800 47,377 01/11/23
Meisner Lara General Counsel and.. General Counsel and Secretary Dec 15 Option 23.03 1,597 36,779 1,297 12/19/22
Meisner Lara General Counsel and.. General Counsel and Secretary Dec 15 Sell 28.26 1,597 45,131 12/19/22
Meisner Lara General Counsel and.. General Counsel and Secretary Dec 12 Option 23.03 16,256 374,376 15,656 12/14/22
Meisner Lara General Counsel and.. General Counsel and Secretary Dec 12 Sell 28.09 16,256 456,631 12/14/22
Fairmount Funds Management LLC - - Aug 17 Buy 23.50 425,531 9,999,978 1,363,764 08/19/22
Violin Jonathan Chief Executive Off.. Chief Executive Officer Jun 01 Sell 12.20 30,000 366,000 480,905 06/02/22
Violin Jonathan Chief Executive Offi.. Chief Executive Officer May 02 Sell 13.04 30,000 391,200 510,905 05/04/22
Violin Jonathan Chief Executive Off.. Chief Executive Officer Apr 01 Sell 18.93 30,000 567,900 540,905 04/05/22
Violin Jonathan Chief Executive Off.. Chief Executive Officer Feb 01 Sell 19.06 30,000 571,800 600,905 02/03/22